Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.

@article{Kumar2012LackOB,
  title={Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.},
  author={Anita Kumar and Ann M Vanderplas and Ann S Lacasce and Maria Alma Rodriguez and Allison L Crosby and Eva M Lepisto and Myron S. Czuczman and Auayporn P. Nademanee and Joyce C. Niland and Leo I Gordon and Michael M. Millenson and Andrew D. Zelenetz and Jonathan W. Friedberg and Gregory Alan Abel},
  journal={Cancer},
  year={2012},
  volume={118 11},
  pages={2944-51}
}
BACKGROUND Little is known about the utility of central nervous system (CNS) prophylaxis for diffuse large B-cell lymphoma (DLBCL) in the rituximab era. The objective of this study was to characterize patterns of CNS prophylaxis for patients who received combined rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy using the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes Database, a prospective cohort study that collects clinical and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
28 Citations
26 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

CNS disease in younger patients ( 60 years) with aggressive lymphoma treated in trials of the German High Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT)

  • N Schmitz, S Zeynalova, B Glass
  • Paper presented at: American Society of…
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…